2020Gene
Gaithersburg, US · 1 known investors
20/20 BioLabs develops laboratory blood tests using machine learning for the early detection of cancers and chronic diseases, including a multi-cancer early detection (MCED) protein tumor marker test and an inflammation biomarker test. Its tests use at-home upper-arm capillary blood collection and target individuals and healthcare providers.
AI & Machine LearningBiotechDigital Health
Founders & leadership
JC
Jonathan CohenExecutive Officer, Director
AS
Anne ShiflettExecutive Officer
JZ
Jiminy ZhouExecutive Officer
VK
Vladimir KnezevicDirector
CP
Caroline PopperDirector
JK
Joel KanterExecutive Officer, Director
DW
Donald WallachDirector
DH
Dean HautamakiDirector
MC
Mr. CohenFounder, CEO & President
DZ
Dr. Zhou
DL
Dr. LebowitzChief Scientific Officer
MB
Mr. Baker
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$70KraisedFeb 2025 · 3 investors · BiotechnologyRule 506(b)
▶$70KraisedFeb 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jonathan CohenExecutive Officer, Director
- Prasanth ReddyDirector
- John G ComptonDirector
- John W. RollinsDirector
- Wei LuDirector
- Richard M. CohenDirector
- Anne ShiflettExecutive Officer
- Jiminy ZhouExecutive Officer
- Michael A RossDirector
- Offering amount
- $3M
- Amount sold
- $70K
- First sale
- Jan 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedFeb 2016 · 66 investors · BiotechnologyRule 506(c)
▶$2.5MraisedFeb 2016 · 66 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Jonathan CohenExecutive Officer, Director
- Caroline PopperDirector
- Dean HautamakiDirector
- Vladimir KnezevicDirector
- Donald WallachDirector
- Joel KanterExecutive Officer, Director
- Offering amount
- $4M
- Amount sold
- $2.5M
- Minimum investment
- $5K
- Sales commissions
- $37.1K
- Placement agents
- LBMZ Securities, Inc.
- First sale
- Oct 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$2MraisedFeb 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2MraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vladimir KnezevicDirector
- Caroline PopperDirector
- Joel KanterExecutive Officer, Director
- Donald WallachDirector
- Jonathan CohenExecutive Officer, Director
- Dean HautamakiDirector
- Offering amount
- $3M
- Amount sold
- $2M
- Minimum investment
- $50K
- Proceeds to insiders
- $150K
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 17 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2014 | $750K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $2.8M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $199.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $217.8K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $183.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2008 | $649.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $165.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $117.9K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2006 | $177.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2006 | $177.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $100K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $99.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $96.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $96.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2004 | $79.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2003 | $97.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.